Monoclonal Gammopathy of Undetermined Significance.
Where this comes from
- Record sourced from PubMed, PMID 36508741.
- Also identified by DOI 10.7326/AITC202212200.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is of considerable clinical importance to primary care physicians given its high prevalence in the general population. MGUS has a variable but lifelong risk for progression to hematologic cancer, such as multiple myeloma, Waldenström macroglobulinemia, or light-chain amyloidosis. In addition, MGUS has been associated with several nonmalignant yet symptomatic disorders that require therapy directed toward eliminating the monoclonal gammopathy. Thus, it is important not only to understand the essentials of diagnosing and monitoring patients with MGUS but also to recognize when to refer patients with MGUS to a specialist.
Medical subject headings
- Monoclonal Gammopathy of Undetermined Significance
- Paraproteinemias
- Multiple Myeloma
- Waldenstrom Macroglobulinemia